Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia

Cai H and Harrison DG: Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res. 87:840–844. 2000. View Article : Google Scholar : PubMed/NCBI

De Nunzio C, Aronson W, Freedland SJ, Giovannucci E and Parsons JK: The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 61:560–570. 2012. View Article : Google Scholar : PubMed/NCBI

Sychlowy A, van der Gaag H and Hannen-Hofheinz I: Hyperkalemia-life-threatening early complication of asphyxia in premature infants. Monatsschr Kinderheilkd. 138:62–65. 1990.(In German). PubMed/NCBI

Saito M, Tsounapi P, Oikawa R, Shimizu S, Honda M, Sejima T, Kinoshita Y and Tomita S: Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH. Sci Rep. 4:38222014. View Article : Google Scholar : PubMed/NCBI

Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I, Tlsty TD and Esserman LJ: Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res. 63:2347–2350. 2003.PubMed/NCBI

Miyake H, Hara I, Kamidono S and Eto H: Oxidative DNA damage in patients with prostate cancer and its response to treatment. J Urol. 171:1533–1536. 2004. View Article : Google Scholar : PubMed/NCBI

Nelson WG, DeWeese TL and DeMarzo AM: The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev. 21:3–16. 2002. View Article : Google Scholar : PubMed/NCBI

Kanwal R, Pandey M, Bhaskaran N, Maclennan GT, Fu P, Ponsky LE and Gupta S: Protection against oxidative DNA damage and stress in human prostate by glutathione S-transferase P1. Mol Carcinog. 53:8–18. 2014. View Article : Google Scholar : PubMed/NCBI

Koul HK, Kumar B, Koul S, Deb AA, Hwa JS, Maroni P, van Bokhoven A, Lucia MS, Kim FJ and Meacham RB: The role of inflammation and infection in prostate cancer: Importance in prevention, diagnosis and treatment. Drugs Today (Barc). 46:929–943. 2010. View Article : Google Scholar : PubMed/NCBI

Wu Q and Ni X: ROS-mediated DNA methylation pattern alterations in carcinogenesis. Curr Drug Targets. 16:13–19. 2015. View Article : Google Scholar : PubMed/NCBI

Raza Y, Khan A, Farooqui A, Mubarak M, Facista A, Akhtar SS, Khan S, Kazi JI, Bernstein C and Kazmi SU: Oxidative DNA damage as a potential early biomarker of Helicobacter pylori associated carcinogenesis. Pathol Oncol Res. 20:839–846. 2014. View Article : Google Scholar : PubMed/NCBI

Fukumoto K, Nagai A, Hara R, Fujii T and Miyaji Y: Tadalafil for male lower urinary tract symptoms improves endothelial function. Int J Urol. 24:206–210. 2017. View Article : Google Scholar : PubMed/NCBI

Yokoyama O, Ozeki A, Suzuki N and Murakami M: Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia. Int J Urol. 25:240–245. 2018. View Article : Google Scholar : PubMed/NCBI

Gotoh D, Torimoto K, Tatsumi Y, Hori S, Yamada A, Miyake M, Morizawa Y, Aoki K, Tanaka N, Hirayama A, et al: Tadalafil, a phosphodiesterase type 5 inhibitor, improves bladder blood supply and restores the initial phase of lower urinary tract dysfunction in diabetic rats. Neurourol Urodyn. 35:444–449. 2017.

Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, Santi R, Filippi S, Sebastianelli A, Nesi G, et al: PDE5 inhibitors blunt inflammation in human BPH: A potential mechanism of action for PDE5 inhibitors in LUTS. Prostate. 73:1391–1402. 2013. View Article : Google Scholar : PubMed/NCBI

Zarifpour M, Nomiya M, Sawada N and Andersson KE: Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia. Prostate. 75:233–241. 2015. View Article : Google Scholar : PubMed/NCBI